Yahav Dafna, Gitman Melissa R, Margalit Ili, Avni Tomer, Leeflang Mariska M G, Husain Shahid
Infectious Diseases Unit, Sheba Medical Center, Ramat-Gan, Israel.
Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Open Forum Infect Dis. 2023 Jul 5;10(8):ofad324. doi: 10.1093/ofid/ofad324. eCollection 2023 Aug.
This is a systematic review and meta-analysis of diagnostic test accuracy studies to assess the predictive value of both tuberculin skin test (TST) and interferon-gamma release assays (IGRA) for active tuberculosis (TB) among solid organ transplantation (SOT) recipients.
Medline, Embase, and the CENTRAL databases were searched from 1946 until June 30, 2022. Two independent assessors extracted data from studies. Sensitivity analyses were performed to investigate the effect of studies with high or low risk of bias. Methodological quality of each publication was assessed using QUADAS-2.
A total of 43 studies (36 403 patients) with patients who were screened for latent TB infection (LTBI) and who underwent SOT were included: 18 were comparative and 25 noncomparative (19 TST, 6 QuantiFERON-TB Gold In-Tube [QFT-GIT]). For IGRA tests taken together, positive predictive value (PPV) and negative predictive value (NPV) were 1.2% and 99.6%, respectively. For TST, PPV was 2.13% and NPV was 95.5%. Overall, PPV is higher when TB burden is higher, regardless of test type, although still low in absolute terms. Incidence of active TB was similar between studies using LTBI prophylaxis (mean incidence 1.22%; 95% confidence interval [CI], .2179-2.221) and those not using prophylaxis (mean incidence 1.045%; 95% CI, 0.2731-1.817; = .7717). Strengths of this study include the large number of studies available from multiple different countries; limitations include absence of gold standard for diagnosis of latent TB and low incidence of active TB.
We found both TST and IGRA had a low PPV and high NPV for the development of active TB posttransplant. Further studies are needed to better understand how to prevent active TB in the SOT population.
这是一项关于诊断试验准确性研究的系统评价和荟萃分析,旨在评估结核菌素皮肤试验(TST)和干扰素-γ释放试验(IGRA)对实体器官移植(SOT)受者活动性结核病(TB)的预测价值。
检索了1946年至2022年6月30日的Medline、Embase和CENTRAL数据库。两名独立评估人员从研究中提取数据。进行敏感性分析以研究偏倚风险高或低的研究的影响。使用QUADAS-2评估每个出版物的方法学质量。
共纳入43项研究(36403例患者),这些患者接受了潜伏性结核感染(LTBI)筛查并接受了SOT:18项为比较性研究,25项为非比较性研究(19项TST,6项管内结核菌素释放试验[QFT-GIT])。综合IGRA试验,阳性预测值(PPV)和阴性预测值(NPV)分别为1.2%和99.6%。对于TST,PPV为2.13%,NPV为95.5%。总体而言,无论试验类型如何,当结核病负担较高时PPV较高,尽管绝对值仍然较低。使用LTBI预防的研究(平均发病率1.22%;95%置信区间[CI],0.2179 - 2.221)和未使用预防的研究(平均发病率1.045%;95%CI,0.2731 - 1.817;P = 0.7717)之间活动性结核病的发病率相似。本研究的优势包括可获得来自多个不同国家的大量研究;局限性包括缺乏潜伏性结核诊断的金标准以及活动性结核病的发病率较低。
我们发现TST和IGRA对移植后活动性结核病的发生均具有低PPV和高NPV。需要进一步研究以更好地了解如何预防SOT人群中的活动性结核病。